Pancreatic Cancer Research

ResearcherThe University of Texas MD Anderson Cancer CenterActive in the last 2 years

Sung Hwan Lee

ORCID-verified (high confidence, 0.95), identity_conf@1As of 7 November 2026

Matched on ORCID iD 0000-0003-3365-0096; OpenAlex author ID A5079567887. Sources: OpenAlex.

Their work

Papers
18 (first author 3, last author 0)
Trials
0
Grants
0
Labs led
0
Collaborators
23
Papers, trials and grants by year

2014: 2 papers · 2015: 1 paper · 2016: 2 papers · 2017: 2 papers · 2018: 2 papers · 2019: 4 papers · 2020: 1 paper · 2021: 1 paper · 2022: 1 paper · 2023: 1 paper · 2024: 1 paper

Papers 18

  1. Differentially expressed genes associated with high metabolic tumor volume served as diagnostic markers and potential therapeutic targets for pancreatic cancer. First author DOI 10.1186/s12967-024-05181-z↗
  2. Development of a metabolite calculator for diagnosis of pancreatic cancer. Co-author DOI 10.1002/cam4.6233↗
  3. Anticancer effect of locally applicable aptamer-conjugated gemcitabine-loaded atelocollagen patch in pancreatic cancer patient-derived xenograft models. Co-author DOI 10.1111/cas.15318↗
  4. MCT4 as a potential therapeutic target to augment gemcitabine chemosensitivity in resected pancreatic cancer. Co-author DOI 10.1007/s13402-021-00643-8↗
  5. Yonsei Criteria, a Potential Linkage to Intratumoral Foxp3⁺/CD8⁺ Ratio for the Prediction of Oncologic Outcomes in Resected Left-Sided Pancreatic Cancer. First author DOI 10.3349/ymj.2020.61.4.291↗
  6. Developing a preoperative serum metabolome-based recurrence-predicting nomogram for patients with resected pancreatic ductal adenocarcinoma. Co-author DOI 10.1038/s41598-019-55016-x↗
  7. Potential Impact of Phellinus linteus on Adherence to Adjuvant Treatment After Curative Resection of Pancreatic Ductal Adenocarcinoma: Outcomes of a Propensity… Co-author DOI 10.1177/1534735418816825↗
  8. Prognostic potential of the preoperative plasma complement factor B in resected pancreatic cancer: A pilot study. Co-author DOI 10.3233/cbm-181847↗
  9. Preoperative Metabolic Tumor Volume2.5 Associated with Early Systemic Metastasis in Resected Pancreatic Cancer: A Transcriptome-Wide Analysis. Co-author DOI 10.5009/gnl18242↗
  10. Different biological behaviors in left-sided pancreatic cancer according to Yonsei criteria: Proposal of a modified Yonsei criteria score. Co-author DOI 10.1016/j.pan.2018.09.001↗
  11. Fluorescence-guided Surgery with Splenic Preservation Prevents Tumor Recurrence in an Orthotopic Nude-mouse Model of Human Pancreatic Cancer. Co-author DOI 10.21873/anticanres.12270↗
  12. The Yonsei criteria as a clinically detectable parameter for excellent prognosis in resected left-sided pancreatic cancer: outcomes of a propensity score-match… Co-author DOI 10.1007/s00464-017-5529-6↗
  13. Splenectomy is associated with an aggressive tumor growth pattern and altered host immunity in an orthotopic syngeneic murine pancreatic cancer model. Co-author DOI 10.18632/oncotarget.21331↗
  14. Adverse oncologic effects of intraoperative transfusion during pancreatectomy for left-sided pancreatic cancer: the need for strict transfusion policy. Co-author DOI 10.1002/jhbp.368↗
  15. Preoperative Volume-Based PET Parameter, MTV2.5, as a Potential Surrogate Marker for Tumor Biology and Recurrence in Resected Pancreatic Cancer. First author DOI 10.1097/md.0000000000002595↗
  16. Pathological Complete Remission of Pancreatic Cancer Following Neoadjuvant Chemoradiation Therapy; Not the End of Battles. Co-author DOI 10.1097/md.0000000000002168↗
  17. Minimally invasive RAMPS in well-selected left-sided pancreatic cancer within Yonsei criteria: long-term (>median 3 years) oncologic outcomes. Co-author DOI 10.1007/s00464-014-3537-3↗
  18. Fatal liver injury complicated by percutaneous catheter drainage after distal pancreatosplenectomy in a patient with pancreatic cancer. Co-author DOI 10.14701/kjhbps.2014.18.2.64↗

Closest collaborators

The 23 strongest of 23 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Chang Moo Kang · 17 shared papers, 2014–2024 · strength 1.94
  2. Ho Kyoung Hwang · 14 shared papers, 2014–2021 · strength 1.39
  3. Woo Jung Lee · 12 shared papers, 2014–2021 · strength 1.18
  4. Min Jung Lee · 3 shared papers, 2019–2023 · strength 0.38
  5. Young‐Ki Paik · 3 shared papers, 2019–2023 · strength 0.38
  6. Baek Gil Kim · 1 shared paper, 2024 · strength 0.26
  7. Nam Hoon Cho · 1 shared paper, 2024 · strength 0.26
  8. Sung Hyun Kim · 2 shared papers, 2017–2019 · strength 0.21
  9. Seoung Yoon Rho · 2 shared papers, 2018–2019 · strength 0.19
  10. Munseok Choi · 1 shared paper, 2023 · strength 0.18
  11. Sung Ill Jang · 1 shared paper, 2023 · strength 0.18
  12. Dong Ki Lee · 1 shared paper, 2023 · strength 0.18
  13. Michael Bouvet · 2 shared papers, 2017–2018 · strength 0.16
  14. Takashi Murakami · 2 shared papers, 2017–2018 · strength 0.16
  15. Robert M. Hoffman · 2 shared papers, 2017–2018 · strength 0.16
  16. Seung Soo Hong · 1 shared paper, 2022 · strength 0.16
  17. Jung Hwan Lee · 1 shared paper, 2022 · strength 0.16
  18. Jeong Youp Park · 1 shared paper, 2014 · strength 0.06
  19. Myeong‐Jin Kim · 1 shared paper, 2015 · strength 0.05
  20. Si Young Song · 1 shared paper, 2015 · strength 0.05
  21. Jinsil Seong · 1 shared paper, 2015 · strength 0.05
  22. Sung Hoon Choi · 1 shared paper, 2014 · strength 0.05
  23. Hoon Sang Chi · 1 shared paper, 2014 · strength 0.05

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.